Clinical Trial

A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I clinical trial evaluating the safety, tolerability, and maximum tolerated dose of MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell therapy expressing a suicide gene, in patients with newly diagnosed glioblastoma. The investigational product is administered intratumorally following surgical resection. This study aims to explore whether MSC11FCD can provide a targeted, localized treatment option during the postsurgical period, potentially addressing residual tumor cells and reducing early recurrence.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-19.
Status change: Not Yet Recruiting → Recruiting 2026-01-20
Trial Details
NCT Number NCT07143812
Lead Sponsor CHA University
Conditions Glioblastoma (GBM), Newly Diagnosed Glioblastoma Multiforme
Enrollment 10 participants
Start Date 2025-10-23
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-22